Prognostic factors (PFs) of survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel (nab-P) plus gemcitabine (G) versus G alone in patients (pts) with metastatic pancreatic cancer (MPC).
Malcolm J. Moore
Consultant or Advisory Role - Celgene (U)
Research Funding - Celgene
Daniel D. Von Hoff
Consultant or Advisory Role - Celgene (U)
Honoraria - Celgene
Research Funding - Celgene
Thomas J. Ervin
Research Funding - Celgene
Francis P. Arena
Research Funding - Celgene
E. Gabriela Chiorean
Research Funding - Celgene
Jeffrey R. Infante
No relevant relationships to disclose
Jeremy K. Hon
No relevant relationships to disclose
Mikhail Yu Biakhov
Research Funding - Celgene
Sunil R. Hingorani
No relevant relationships to disclose
Vinod Ganju
No relevant relationships to disclose
Colin D. Weekes
Consultant or Advisory Role - Celgene
Honoraria - Celgene
Werner Scheithauer
Consultant or Advisory Role - Celgene
Honoraria - Celgene
Research Funding - Celgene
Ramesh K. Ramanathan
Consultant or Advisory Role - Celgene (U)
Honoraria - Abraxis BioScience
Research Funding - Celgene
Josep Tabernero
Consultant or Advisory Role - Celgene
David Goldstein
Consultant or Advisory Role - Celgene (U)
Research Funding - Celgene
Xinyu Wei
Employment or Leadership Position - Celgene
Stock Ownership - Celgene
Alfredo Romano
Employment or Leadership Position - Celgene
Stock Ownership - Celgene